Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 40

Trans-spinal magnetic stimulation to modulate cortical excitability in healthy adults

Official title: Effects of Trans-spinal Magnetic Stimulation on Cortical Excitability in Healthy Individuals

Run by Universidade Federal de Pernambuco · NCT07026760 · Data updated 2026-11-12

We test whether different frequencies and intensities of trans‑spinal magnetic stimulation change motor cortex excitability in healthy adults aged 18–40.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 40 Years
SexAll
Enrollment18 (estimated)
SponsorUniversidade Federal de Pernambuco
Academic / other
Locations1 site (Recife, Pernambuco)
StatusRecruiting
StartedOctober 1, 2022
Main results expectedSeptember 30, 2025
Study endsOctober 30, 2025
Registry record updatedJune 18, 2025
Trial IDNCT07026760 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are healthy, right‑handed adults aged 18–40 (women using consistent contraception) with no neurological or musculoskeletal diagnoses, no seizure history, and no disqualifying metallic implants.

Probably not a fit

People who are pregnant, have a history of seizures, have metallic implants in the head/spine/face/heart, have diagnosed neurological or musculoskeletal conditions, or use substances that alter nervous system excitability are excluded and unlikely to gain direct benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind crossover trial applies trans‑spinal magnetic stimulation at the C7 level using three frequencies (1, 10, 25 Hz) and three intensities (90%, 100%, 110% of resting motor threshold) across sequential phases. Healthy, right‑handed adults undergo pre‑ and post‑intervention measurements of motor‑evoked potentials (MEP), intracortical inhibition (ICI), and intracortical facilitation (ICF). Statistical comparisons will use ANOVA or Friedman tests to determine whether neuromodulatory effects vary by stimulation parameters. The protocol is approved by the Federal University of Pernambuco ethics committee and data will be stored securely.

Why it matters

Potential benefit: If successful, the findings could identify optimal stimulation parameters to guide noninvasive neuromodulation approaches for neurological rehabilitation.

How similar studies have gone: Prior transcranial and some trans‑spinal magnetic stimulation work shows that noninvasive stimulation can alter cortical excitability, but parameter‑specific effects for TsMS are still relatively novel and incompletely established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Healthy adults aged 18-40 years, of both sexes; right-handed (confirmed via the Edinburgh Handedness Inventory); and for women, consistent use of contraceptive medication to mitigate hormonal influences on nervous system excitability.

Exclusion Criteria:

Pregnancy; history of seizures or epilepsy; metallic implants in the head, spine, face, or heart; diagnosed neurological or musculoskeletal conditions that could interfere with assessments or interventions; or use of substances that alter nervous system excitability.

Where it's running

  • Universidade Federal de Pernambuco
    Recife, Pernambuco, Brazil
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.